Chronic Refractory Cough Market is segmented By Treatment (Antitussives, Expectorants, Combination Medications), By Route of Administration (Oral, Inhalation, Injectable) ....
Market Size in USD
CAGR8.2%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 8.2% |
Market Concentration | Medium |
Major Players | Merck & Co., Inc., Bellus Health Inc., Bayer AG, AstraZeneca plc, GlaxoSmithKline plc |
The chronic refractory cough market is estimated to be valued at USD 1.62 Bn in 2024 and is expected to reach USD 2.82 Bn by 2031, growing at a compound annual growth rate (CAGR) of 8.2% from 2024 to 2031. The increasing prevalence of chronic respiratory diseases and growing demand for non-codeine medications are major factors contributing to the growth of this market.